Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2008

PerkinElmer Obtains Finnish Site for Genetic Screening Services

  • PerkinElmer signed a long-term lease for an industrial/office research facility in Turku, Finland. It will reportedly serve as the headquarters for the company’s genetic screening business, which provides solutions for neonatal, clinical, and prenatal screening and diagnostics. A significant portion will also be used for R&D.

    The transaction was facilitated through investment firm W. P. Carey & Co. CPA®:14, W. P. Carey & Co.’s publicly held nontraded REIT affiliate, acquired the Turku site for approximately 10 million. The facility is being leased to Wallac Oy, a subsidiary of PerkinElmer.

    The acquisition is a follow-on transaction to an approximately 28 million sale-leaseback of an adjacent research and production building that CPA:14 completed with PerkinElmer in 2001. Both properties are located in Turku’s Bio Valley.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »